CYCN

Cyclerion Therapeutics Inc (CYCN) | Rumor.io

Cyclerion Therapeutics

CYCN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,943

Bullish sentiment (50-day avg)88%

Price to earnings ratio-27.9

Market capitalization20.7M

Earnings per share-11.6

Dividend yield (TTM)—

Revenue (annual)2.1M

Net income (annual)-3.5M

Social

What share of all stock conversation is about CYCN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Sep 9

Cyclerion Therapeutics has completed its merger with Korsana Biosciences, with the combined company operating as Korsana and focusing on treatments for neurodegenerative diseases.
The merger resulted in a 1:7 reverse stock split, with Cyclerion's shares being exchanged for Korsana's shares at a ratio of 0.2074 combined shares per Korsana share.
The reverse split was completed on September 9, 2026, and the new ticker symbol for Cyclerion Therapeutics is KRSA.

Generated by AI

Sentiment

Of the messages about CYCN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	60% -29.71	76.41% +5.52
Bearish	—	—	40% +29.71	23.59% -5.52

Bullish· Apr 9

Cyclerion Therapeutics' ($CYCN) stock price has exploded, surging by 28.37% to $3.71, breaking through the $3.20 resistance level.
The company's recent Korsana merger and $380M financing deal have driven a 350% surge in its stock price, with further growth expected.
$CYCN is poised to continue its upward momentum, with some analysts predicting it will shoot above $10 by July.

Bearish· Apr 9

$CYCN's recent gains may be unsustainable, with some investors expecting a retest of lower prices.
The company's financial situation is a concern, with some comparing it to another biotech firm, Cyclerion Therapeutics, which was hemorrhaging money and raising capital through ATM offerings.
The merger with another company may lead to a significant decline in $CYCN's value, with some estimates suggesting a collapse to 4-10 cents per share.

Generated by AI

Topics

Of the messages about CYCN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	96.15%	44.14%
Technical Analysis	0%	0%	0%	30.85%
Controversies	0%	0%	3.85%	0.28%
Analysts	0%	0%	0%	11.44%
Earnings	0%	0%	0%	0.09%
Macro	0%	0%	0%	13.2%

Announcements· Apr 9

Cyclerion Therapeutics, Inc. (CYCN) announced an all-stock deal with Korsana Biosciences, sparking a merger catalyst and a fresh biotech M&A story.
CYCN surged to $3.65, up 26.12%, after securing a major government contract, building on the transformative momentum from its Korsana merger and $380M financing deal.
CYCN broke out to $3.71, fueled by the 350% surge from its Korsana merger and $380M financing deal, with a confirmed breakout toward a $5.04 target.

Technical Analysis· Apr 9

$CYCN broke out above $3.20 resistance on 1.37M volume, targeting $5.04.
The stock surged 28.37% to $3.71, fueled by a 350% increase from the Korsana merger and $380M financing deal.
A close above $3.20 could complete a chart gap at $3.50.

Generated by AI

Community

Of the messages about CYCN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	85.71%	13.94%	32.13%
Newcomers	0%	14.29%	86.06%	67.87%

Regulars· Apr 1

The merger between Cyclerion Therapeutics and Korsana Biosciences is expected to be completed, with the combined company operating as Korsana Biosciences and trading under the ticker KRSA, and the transaction supported by an oversubscribed private financing of approximately $380 million.
The merger is expected to provide a cash runway into 2029 and adds KRSA-028, a therapeutic for Alzheimer's disease, to Cyclerion's pipeline.
The combined company is expected to benefit from the merger, with the ownership at close consisting of ~1.5% Cyclerion shareholders and ~98.5% Korsana shareholders, and the deal terms including an all-stock merger and $380 million in private financing.

Newcomers· Apr 9

The newcomer is excited about Cyclerion Therapeutics' recent government contract and its potential impact on the company's pipeline.
The newcomer is optimistic about the company's recent merger with Korsana and its $380M financing deal, which has led to a 350% surge.
The newcomer is focusing on the technical analysis of the stock's recent breakout and the resistance level it has smashed, with a target of $5.04.

Generated by AI

News

Cyclerion Shareholders Approve Key Measures for Korsana Merger

Detailed price information for Cyclerion Therapeutics Inc (CYCN-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about CYCN also mention

#	Name	Attention
1	Surrozen, Inc.SRZN	0%0
2	Sky Quarry Inc.SKYQ	0%-0.01
3	Gaxos.ai Inc.GXAI	0%0
4	Genenta Science S.p.A. Sponsored ADRGNTA	0%0
5	EpicQuest Education Group International LimitedEEIQ	0%0
6	BullFrog AI Holdings, Inc.BFRG	0%0
7	BT Brands, Inc.BTBD	0%0
8	Flash Sports & Media, Inc.UGRO	0%new
9	Linkers Industries LimitedLNKS	0%0
10	Huachen AI Parking Management Technology Holding Co., Ltd. Class A Ordinary SharesHCAI	0%new

Cyclerion Therapeutics Inc

Healthcare
Biotechnology

Korsana Biosciences, Inc. Common Stock represents the equity of Korsana Biosciences, a biotechnology company focused on developing novel therapies for neurodegenerative diseases. The company’s current work centers on brain-penetrant therapeutics built around its proprietary THETA blood-brain-barrier shuttle platform, which is designed to improve delivery of large molecules into the central nervous system. Its lead program, KRSA-028, is an investigational antibody targeting amyloid beta for Alzheimer’s disease, alongside additional pipeline assets aimed at other neurodegenerative conditions. Korsana’s business is centered on discovering, advancing, and eventually commercializing precision-engineered medicines for serious brain disorders, making it a specialized participant in the biopharmaceutical market focused on central nervous system innovation. The company is based in Waltham, Massachusetts.

Website

Location

245 First Street, Riverview II

Cambridge, MA, 02142

United States

Social

What share of all stock conversation is about CYCN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Sep 9

Cyclerion Therapeutics has completed its merger with Korsana Biosciences, with the combined company operating as Korsana and focusing on treatments for neurodegenerative diseases.
The merger resulted in a 1:7 reverse stock split, with Cyclerion's shares being exchanged for Korsana's shares at a ratio of 0.2074 combined shares per Korsana share.
The reverse split was completed on September 9, 2026, and the new ticker symbol for Cyclerion Therapeutics is KRSA.

Generated by AI

Sentiment

Of the messages about CYCN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	60% -29.71	76.41% +5.52
Bearish	—	—	40% +29.71	23.59% -5.52

Bullish· Apr 9

Cyclerion Therapeutics' ($CYCN) stock price has exploded, surging by 28.37% to $3.71, breaking through the $3.20 resistance level.
The company's recent Korsana merger and $380M financing deal have driven a 350% surge in its stock price, with further growth expected.
$CYCN is poised to continue its upward momentum, with some analysts predicting it will shoot above $10 by July.

Bearish· Apr 9

$CYCN's recent gains may be unsustainable, with some investors expecting a retest of lower prices.
The company's financial situation is a concern, with some comparing it to another biotech firm, Cyclerion Therapeutics, which was hemorrhaging money and raising capital through ATM offerings.
The merger with another company may lead to a significant decline in $CYCN's value, with some estimates suggesting a collapse to 4-10 cents per share.

Generated by AI

Topics

Of the messages about CYCN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	96.15%	44.14%
Technical Analysis	0%	0%	0%	30.85%
Controversies	0%	0%	3.85%	0.28%
Analysts	0%	0%	0%	11.44%
Earnings	0%	0%	0%	0.09%
Macro	0%	0%	0%	13.2%

Announcements· Apr 9

Cyclerion Therapeutics, Inc. (CYCN) announced an all-stock deal with Korsana Biosciences, sparking a merger catalyst and a fresh biotech M&A story.
CYCN surged to $3.65, up 26.12%, after securing a major government contract, building on the transformative momentum from its Korsana merger and $380M financing deal.
CYCN broke out to $3.71, fueled by the 350% surge from its Korsana merger and $380M financing deal, with a confirmed breakout toward a $5.04 target.

Technical Analysis· Apr 9

$CYCN broke out above $3.20 resistance on 1.37M volume, targeting $5.04.
The stock surged 28.37% to $3.71, fueled by a 350% increase from the Korsana merger and $380M financing deal.
A close above $3.20 could complete a chart gap at $3.50.

Generated by AI

Community

Of the messages about CYCN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	85.71%	13.94%	32.13%
Newcomers	0%	14.29%	86.06%	67.87%

Regulars· Apr 1

The merger between Cyclerion Therapeutics and Korsana Biosciences is expected to be completed, with the combined company operating as Korsana Biosciences and trading under the ticker KRSA, and the transaction supported by an oversubscribed private financing of approximately $380 million.
The merger is expected to provide a cash runway into 2029 and adds KRSA-028, a therapeutic for Alzheimer's disease, to Cyclerion's pipeline.
The combined company is expected to benefit from the merger, with the ownership at close consisting of ~1.5% Cyclerion shareholders and ~98.5% Korsana shareholders, and the deal terms including an all-stock merger and $380 million in private financing.

Newcomers· Apr 9

The newcomer is excited about Cyclerion Therapeutics' recent government contract and its potential impact on the company's pipeline.
The newcomer is optimistic about the company's recent merger with Korsana and its $380M financing deal, which has led to a 350% surge.
The newcomer is focusing on the technical analysis of the stock's recent breakout and the resistance level it has smashed, with a target of $5.04.

Generated by AI

Cyclerion Therapeutics

Social

Sep 9

Bullish· Apr 9

Bearish· Apr 9

Announcements· Apr 9

Technical Analysis· Apr 9

Regulars· Apr 1

Newcomers· Apr 9

Cyclerion Shareholders Approve Key Measures for Korsana Merger

Also Discussed

Cyclerion Therapeutics Inc

Company Information

Location

Cyclerion Shareholders Approve Key Measures for Korsana Merger

Also Discussed

Social

Sep 9

Bullish· Apr 9

Bearish· Apr 9

Announcements· Apr 9

Technical Analysis· Apr 9

Regulars· Apr 1

Newcomers· Apr 9